It is known that intracerebroventricular (ICV) administration of a low dose of interleukin-1β (IL-1β) induces hyperalgesia and that this effect can be inhibited by α-melanophore-stimulating hormone (α-MSH). To identify the part of the brain that is affected by hyperalgesia-induced IL-1β and the possible site of α-MSH inhibition, we have examined Fos expression in the rat brain in response to ICV microinjection of α-MSH and/or IL-1β. Following injection of 10 pg IL-1β, hyperalgesia was induced and Fos became expressed in the paraventricular nucleus (PVN) of the hypothalamus and in the arcuate nucleus (ARC), which contains α-MSH-producing neurons. IL-1β injection did not induce Fos expression in the pars intermedia of the pituitary gland, which contains endocrine melanotrope cells that release α-MSH into the systemic circulation. ICV co-injection of IL-1β with 30 ng α-MSH fully inhibited both hyperalgesia and Fos expression in the PVN and the ARC. We conclude that PVN neurons are activated by hyperalgesic IL-1β and propose that this effect is abolished by α-MSH possibly released from the ARC but not from the pituitary gland.

1.
Hori T, Oka T, Hosoi M, Abe M, Oka K: Hypothalamic mechanisms of pain modulatory actions of cytokines and prostaglandin E2. Ann NY Acad Sci 2000;917:106–120.
2.
Tatro JB, Sinha PS: The central melanocortin system and fever. Ann NY Acad Sci 2003;994:246–257.
3.
Eberle AN: Effects of the immune system; in Eberle AN (ed): The Melanotropins. Chemistry, Physiology and Mechanisms of Action. Basel, Karger, 1988, pp 266–268.
4.
Oka T, Aou S, Hori T: Intracerebroventricular injection of interleukin-1β induces hyperalgesia in rats. Brain Res 1993;624:61–68.
5.
Oka T, Aou S, Hori T: Intracerebroventricular injection of interleukin-1β enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats. Brain Res 1994;656:236–244.
6.
Morgan JI, Curran T: Stimulus-transcription coupling in the nervous system: Involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 1991;14:421–451.
7.
Rivest S, Torres G, Rivier C: Differential effects of central and peripheral injection of interleukin-1β on brain c-fos expression and neuroendocrine functions. Brain Res 1992;587:13–23.
8.
Rivest S, Rivier C: Interleukin-1β inhibits the endogenous expression of the early gene c-fos located within the nucleus of LH-RH neurons and interferes with hypothalamic LH-RH release during proestrus in the rat. Brain Res 1993;613:132–142.
9.
Chang SL, Patel NA, Romero AA, Thompson J, Zadina JE: Fos expression induced by interleukin-1 or acute morphine treatment in the rat hypothalamus is attenuated by chronic exposure to morphine. Brain Res 1996;736:227–236.
10.
Chang SL, Ren T, Zadina JE: Interleukin-1 activation of Fos proto-oncogene protein in the rat hypothalamus. Brain Res 1993;617:123–130.
11.
Day HE, Akil H: Differential pattern of c-fos mRNA in rat brain following central and systemic administration of interleukin-1β: Implications for mechanism of action. Neuroendocrinology 1996;63:207–218.
12.
Jenks BG, Verburg-van Kemenade BML, Martens GJM: Pro-opiomelanocortin in the amphibian pars intermedia: A neuroendocrine model; in Hadley ME (ed): The Melanotropic Peptides, vol 1: Source, Synthesis, Chemistry, Secretion, Circulation, and Metabolism. Boca Raton, CRC Press, 1988, pp 103–126.
13.
Tonon MC, Danger JM, Lamacz M, Leroux P, Adjeroud S, Anderson A, Verburg-van Kemenade BML, Jenks BG, Pelletier G, Stoeckel L, Burlet A, Kupryszewski G, Vaudry H: Multihormonal control of melanotropin secretion in cold-blooded vertebrates; in Hadley ME (ed): The Melanotropic Peptides, vol 1: Source, Synthesis, Chemistry, Secretion, Circulation, and Metabolism. Boca Raton, CRC Press, 1988, pp 127–170.
14.
Eberle AN: Effects of MSH on pigment cells; in Eberle AN (ed): The Melanotropins. Chemistry, Physiology and Mechanisms of Action. Basel, Karger, 1988, pp 210–252.
15.
Jenks BG, Leenders HJ, Martens GJM, Roubos EW: Adaptation physiology: The functioning of pituitary melanotrope cells during background adaptation of the amphibian Xenopus laevis. Zool Sci 1993;10:1–11.
16.
Vaudry H, Eberle AN (eds): The melanotropic peptides. Ann NY Acad Sci 1993;680:687.
17.
Tonosaki Y, Nishiyama K, Honda T, Ozaki N, Sugiura Y: D2-like dopamine receptor mediates dopaminergic or γ-aminobutyric acidergic inhibition of melanophore-stimulating hormone release from the pars intermedia in frogs (Rana nigromaculata). Endocrinology 1995;136:5260–5265.
18.
Roubos EW: Background adaptation by Xenopus laevis: A model for studying neuronal information processing in the pituitary pars intermedia. Comp Biochem Physiol 1997;118:533–550.
19.
Dube D, Lissitzky JC, Leclerc R, Pelletier G: Localization of α-melanocyte-stimulating hormone in rat brain and pituitary. Endocrinology 1978;102:1283–1291.
20.
Eberle AN: MSH in the central nervous system; in Eberle AN (ed): The Melanotropins. Chemistry, Physiology and Mechanisms of Action. Basel, Karger, 1988, pp 158–169.
21.
Inagaki S: Hypothalamus; in Tohyama M, Shioya Y (eds): Chemical Neuroanatomy (in Japanese). Osaka, Koseisha, 1987, pp 167–216.
22.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press, 1982, pp 1–271.
23.
Sekiguchi Y, Konnai Y, Kikuchi S, Sugiura Y: An anatomic study of neuropeptide immunoreactivities in the lumbar dura mater after lumbar sympathectomy. Spine 1996;21:925–930.
24.
Honda T, Oda S, Ozaki N, Tonosaki Y, Nishiyama K, Sugiura Y: Neuronal damage of the primary afferent neurons elicits Fos expression even in spinal dorsal horn of the capsaicin-induced analgesic rats. Pain Res 1995;10:61–70.
25.
Tonosaki Y, Cruijsen PMJM, Nishiyama K, Yaginuma H, Roubos EW: Low temperature stimulates α-MSH secretion and inhibits background adaptation in Xenopus laevis. J Neuroendocrinol 2004;16:894–905.
26.
Dawson B, Trapp RG: Basic and Clinical Biostatistics. New York, McGraw-Hill, 2001.
27.
Bliss C: Statistics in Biology. New York, McGraw-Hill, 1967.
28.
Riffenburgh RH: Statistics in Medicine. San Diego, Academic Press, 1999.
29.
Shapiro HH, Wilk MB: An analysis of variance test for normality. Biometrics 1965;52:591–611.
30.
Veening JG, van der Meer MJ, Joosten H, Hermus AR, Rijnkels CE, Geeraedts LM, Sweep CG: Intravenous administration of interleukin-1β induces Fos-like immunoreactivity in corticotropin-releasing hormone neurons in the paraventricular hypothalamic nucleus of the rat. J Chem Neuroanat 1993;6:391–397.
31.
Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB, Elmquist JK: Expression of melanocortin-4 receptor mRNA in the central nervous system of the rat. J Comp Neurol 2003;457:213–235.
32.
Jegou S, Boutelet I, Vaudry H: Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus. J Neuroendocrinol 2000;12:501–505.
33.
Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD: Localization of the melanocortin-4 receptor in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994;8:1298–1308.
34.
Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD: Identification of a receptor for γ-melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 1993;90:8856–8860.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.